Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Private label desloratadine coming

This article was originally published in The Tan Sheet

Executive Summary

Perrigo may launch a desloratadine anti-allergy product in July 2012 or sooner under circumstances outlined in a recent Hatch-Waxman litigation settlement, the Allegan, Mich.-based private labeler announced Dec. 4. The allergy product is equivalent to Schering-Plough's Clarinex 5 mg tablets, which Wolters Kluwer estimates sold $300 million in the 12 months ending October 2008, Perrigo says. The firm says it may launch the product as a prescription or OTC product depending on its status at the time of the launch

You may also be interested in...



'Peoples' Hope' Remdesivir Results Due Soon - What To Look For?

The first data readout for remdesivir, the much anticipated antiviral for the coronavirus pandemic, is expected in days. Scrip surveys antiviral development and regulatory experts to gauge their interest and the key aspects to watch for in the milestone announcement.

Coronavirus Update: FDA Fast-Tracks Blood Plasma Trials, Novavax Closes In On Vaccine Start

‘We Need Your COVID-19 Testing capacity’ UK Health Secretary Tells Life Science Firms

The UK has an “excellent but small diagnostics industry,” so it needs further testing support from related life science industries to tackle the COVID-19 crisis. One of the outcomes of this could be the creation of new big diagnostics industry players.

Topics

UsernamePublicRestriction

Register

PS102389

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel